Stay updated on Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedRevision label updated from v3.5.4 to v3.5.5 on the page, indicating a minor behind-the-scenes update to the site's revision history.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page's revision label has been updated to v3.5.4, signaling a newer release of the site. This update does not alter the displayed study details or navigation.SummaryDifference0.0%

- Check43 days agoChange DetectedThe page metadata shows an interface/release revision bump from v3.5.2 to v3.5.3, with no changes to the underlying ClinicalTrials.gov study content.SummaryDifference0.0%

- Check50 days agoChange Detected- Revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check58 days agoChange DetectedUpdate of the Italy location entry from Padua, Italy, 35128 to Padova, Italy, 35128.SummaryDifference0.0%

- Check65 days agoChange DetectedAdded a new resource entry for Cutaneous neuroendocrine carcinoma under the Genetic and Rare Diseases Information Center resources in the study page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.